Welcome to our dedicated page for Voyager Therapeutics SEC filings (Ticker: VYGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Voyager Therapeutics, Inc. filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing neurotherapeutics for central nervous system diseases. Its Form 8-K reports include quarterly and annual financial results, corporate updates, Regulation FD investor presentations, executive officer transitions and related exhibits covering pipeline and platform information.
Proxy materials describe annual meeting matters such as director elections, advisory executive compensation votes, auditor ratification, charter matters and proposals involving authorized capital. The filing record also identifies Voyager’s common stock, par value and Nasdaq Global Select Market listing, and formalizes governance and capitalization disclosures relevant to its public-company status.
Voyager Therapeutics (VYGR) notice of proposed sale of 9,406 shares of common stock under Section 144, with the transaction dated 05/15/2026. The filing notes an option granted on 02/06/2026 and lists 60,421,287 shares outstanding as of 05/15/2026 as a context figure. The record shows a prior sale of 4,668 shares on 02/24/2026 generating $17,588.09 in proceeds.
Voyager Therapeutics reported first quarter 2026 results and highlighted progress across its neurology pipeline. Collaboration revenue was $2.6 million, and the company recorded a net loss of $27.9 million, or $0.47 per share, compared with a $31.0 million loss a year earlier.
Research and development expenses fell to $24.6 million, and general and administrative costs declined to $8.3 million, reflecting lower operating spend. Voyager ended the quarter with $171.7 million in cash, cash equivalents and marketable securities, which it expects to fund operations into 2028.
On the pipeline, VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology studies, with clinical entry expected in the second half of 2026. The company also plans mid‑2026 third‑party tau data, first‑in‑human dosing of VY1706, and tau PET imaging efficacy data for antibody VY7523 in late 2026.
Voyager Therapeutics, Inc. reported a net loss of $27.9 million for the three months ended March 31, 2026, slightly improved from $31.0 million a year earlier. Collaboration revenue was $2.6 million, down from $6.5 million, mainly from Neurocrine and Novartis agreements.
Research and development expense fell to $24.6 million from $31.5 million as the company reprioritized its pipeline, including lower spend on discontinued and completed programs while ramping its tau gene therapy candidate VY1706. General and administrative costs declined to $8.3 million.
Cash, cash equivalents, and marketable securities totaled $171.7 million as of March 31, 2026, and management currently expects this, along with collaboration reimbursements and interest income, to fund planned operations into 2028. The company had 60.4 million common shares outstanding as of April 30, 2026.
Voyager Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 9, 2026. Stockholders of record on April 13, 2026, when 60,416,887 common shares were outstanding, may vote online, by phone, mail, or during the live webcast.
Proposals include electing three Class II directors to terms ending at the 2029 annual meeting, an advisory vote on named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor for the year ending December 31, 2026.
Voyager is also seeking approval of a charter amendment to increase authorized capital stock from 125,000,000 to 245,000,000 shares, including an increase in authorized common stock from 120,000,000 to 240,000,000 shares. The Board unanimously recommends voting FOR all four main proposals.
Voyager Therapeutics, Inc. announced a planned finance leadership transition. Chief Financial Officer Nathan Jorgensen, Ph.D. has decided to resign from his roles, effective May 8, 2026, to pursue a new opportunity, and the company states his departure does not stem from any disagreement.
Effective at the same time, long‑tenured executive Robin Swartz, currently Chief Operating Officer and Chief Business Officer, will become principal financial officer and treasurer. Amy Quinlan, the company’s Vice President of Finance, will become principal accounting officer and is expected to enter into Voyager’s standard indemnification agreement.
Voyager Therapeutics, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held virtually on June 9, 2026. The filing seeks approval of director elections, an advisory vote on executive compensation, auditor ratification, and a Charter Amendment Proposal to increase authorized shares.
The Charter Amendment Proposal would amend the Fifth Amended and Restated Certificate of Incorporation to increase authorized shares from 125,000,000 to 245,000,000 and authorized common stock from 120,000,000 to 240,000,000. The record date for voting is April 13, 2026.
Voyager Therapeutics, Inc. President and CEO Alfred Sandrock reported an open-market sale of 11,511 shares of common stock at a weighted average price of $3.87 per share. The transaction occurred under a durable automatic sale instruction to cover tax withholding on restricted stock units that vested on April 1, 2026.
The filing notes the sale was not a discretionary trade by Sandrock. Following this sell-to-cover transaction, he directly holds 472,549 shares of Voyager Therapeutics common stock.
Shiferman Gregory L. reported acquisition or exercise transactions in this Form 4 filing.
Voyager Therapeutics, Inc. granted 50,000 restricted stock units (RSUs) to SVP and General Counsel Gregory L. Shiferman as equity compensation. Each RSU represents one share of common stock upon vesting.
The award was granted on April 1, 2026 under the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan. The RSUs vest over three years: one-third on the first anniversary of the grant date and one-third on each of the next two anniversaries, contingent on his continued service. After this grant, he holds 50,000 shares/RSUs directly.
Issuer submitted a Form 144 notice listing 11,511 shares of Common stock associated with Restricted Stock Vesting and compensation, with an execution date noted as 04/01/2026. The filing also lists three recent sales by Alfred W. Sandrock Jr. on 02/10/2026, 02/18/2026, and 02/24/2026 for 12,192, 11,732, and 14,197 shares respectively.